Lopurin, Duzallo(allopurinol)
Allopurinol, Aloprim, Duzallo, Lopurin, Zyloprim (allopurinol) is a small molecule pharmaceutical. Allopurinol was first approved as Lopurin on 1982-01-01. It is used to treat gout in the USA. It has been approved in Europe to treat gout. The pharmaceutical is active against xanthine dehydrogenase/oxidase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Allopurinol, Aloprim, Lopurin, Zyloprim (discontinued: Allopurinol, Lopurin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Allopurinol sodium
Allopurinol
Allopurinol
+
Lesinurad
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DUZALLO | Ironwood Pharmaceuticals | N-209203 DISCN | 2017-08-18 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| allopurinol | ANDA | 2025-03-05 |
| allopurinol sodium | ANDA | 2022-03-01 |
| aloprim | New Drug Application | 2022-02-18 |
| zyloprim | ANDA | 2018-02-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| gout | EFO_0004274 | D006073 | M10 |
| hyperuricemia | — | D033461 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
HCPCS
No data
Clinical
Clinical Trials
215 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gout | D006073 | EFO_0004274 | M10 | 3 | 20 | 20 | 12 | 12 | 64 |
| Hyperuricemia | D033461 | — | — | 2 | 15 | 6 | 5 | 5 | 31 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 4 | 4 | 1 | 5 | 7 | 21 |
| Syndrome | D013577 | — | — | 2 | 10 | 2 | 2 | 1 | 16 |
| Chronic renal insufficiency | D051436 | — | N18 | 4 | 3 | — | 2 | 4 | 13 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 4 | 2 | 3 | 1 | 1 | 10 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 6 | 1 | 3 | — | 9 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 7 | 2 | 1 | — | 9 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 3 | 2 | 1 | 6 |
| Renal insufficiency | D051437 | — | N19 | — | 1 | 1 | 2 | 1 | 5 |
Show 33 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 6 | 17 | 2 | — | 1 | 23 |
| Lymphoma | D008223 | — | C85.9 | 5 | 12 | 2 | — | 1 | 18 |
| Lymphoid leukemia | D007945 | — | C91 | 4 | 11 | 1 | — | — | 14 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 3 | 8 | 2 | — | 1 | 13 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 2 | 2 | — | 1 | 6 |
| Neoplasms | D009369 | — | C80 | 1 | 4 | 1 | — | — | 6 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | 2 | — | 1 | 4 |
| Tumor lysis syndrome | D015275 | — | E88.3 | — | 1 | 2 | — | — | 3 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 3 | 3 | — | — | 3 |
| Fibrosis | D005355 | — | — | — | 3 | 3 | — | — | 3 |
Show 29 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | 7 | — | — | 1 | 10 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | 7 | — | — | — | 7 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 5 | — | — | — | 7 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 2 | 5 | — | — | — | 6 |
| Preleukemia | D011289 | — | — | 2 | 5 | — | — | — | 6 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 5 | — | — | 1 | 6 |
| Burkitt lymphoma | D002051 | — | C83.7 | — | 5 | — | — | — | 5 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 3 | — | — | — | 5 |
| Myeloid leukemia | D007951 | — | C92 | — | 5 | — | — | — | 5 |
| Plasmacytoma | D010954 | — | C90.3 | 2 | 2 | — | — | — | 4 |
Show 44 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
| Heart disease risk factors | D000082742 | — | — | 3 | — | — | — | — | 3 |
| Vasoconstriction | D014661 | — | — | 2 | — | — | — | — | 2 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | — | — | — | — | 1 |
| Graft vs host disease | D006086 | — | D89.81 | 1 | — | — | — | — | 1 |
| Fasting | D005215 | EFO_0002756 | — | 1 | — | — | — | — | 1 |
| Vasodilation | D014664 | — | — | 1 | — | — | — | — | 1 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | — | — | — | — | 1 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | — | — | — | — | 1 |
| Intestinal diseases | D007410 | — | K63.9 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatic diseases | D012216 | — | M79.0 | — | — | — | — | 1 | 1 |
| Rheumatic fever | D012213 | EFO_1001160 | I00-I02 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | — | 1 | 1 |
| Liver transplantation | D016031 | EFO_0010682 | — | — | — | — | — | 1 | 1 |
| Pathologic constriction | D003251 | — | — | — | — | — | — | 1 | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | — | — | — | 1 | 1 |
| Eisenmenger complex | D004541 | — | I27.83 | — | — | — | — | 1 | 1 |
| Stevens-johnson syndrome | D013262 | EFO_0004276 | L51.1 | — | — | — | — | 1 | 1 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 1 | 1 |
| Endoscopic retrograde cholangiopancreatography | D002760 | — | — | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Allopurinol |
| INN | allopurinol |
| Description | Allopurinol is a bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring. It has a role as a radical scavenger, a gout suppressant, an antimetabolite and an EC 1.17.3.2 (xanthine oxidase) inhibitor. It is an organic heterobicyclic compound and a nucleobase analogue. It derives from a hydride of a 1H-pyrazolo[4,3-d]pyrimidine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Oc1ncnc2[nH]ncc12 |
Identifiers
| PDB | — |
| CAS-ID | 315-30-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1467 |
| ChEBI ID | 40279 |
| PubChem CID | 135401907 |
| DrugBank | DB00437 |
| UNII ID | 63CZ7GJN5I (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Allopurinol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 20,162 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
25,071 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use